Maiva Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Maiva Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $4.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Maiva Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $4.5M Trade | TransData Nexus

Maiva Pharma Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $4.5M Total Trade · DGFT Verified

Maiva Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $4.5M across 4 products in 4 therapeutic categories. Based on 92 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Diltiazem ($2.3M), Furosemide ($1.6M), Ephedrine ($350.0K).

Maiva Pharma Private Limited — Export Portfolio & Destination Treemap

Maiva Pharma Private Limited pharmaceutical export portfolio — 4 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Maiva Pharma Private Limited? — Company Overview & Market Position

Maiva Pharma Private Limited, established on February 5, 1993, is a privately held pharmaceutical company headquartered in Bangalore North, Karnataka, India. The company operates under the Corporate Identification Number (CIN) U24231KA1993PTC013976 and is registered with the Registrar of Companies, Bangalore. As of the latest available data, Maiva Pharma has an authorized capital of ₹310.3 million and a paid-up capital of ₹138.4 million.

In the fiscal year ending March 31, 2025, Maiva Pharma reported a total revenue of ₹1,000 million, marking a 28.82% increase from the previous year. The company's net worth also saw a significant rise of 36.72% during the same period. The workforce comprises approximately 751 professionals, reflecting the company's substantial operational scale. Maiva Pharma's official website is www.maivapharma.com.

What Does Maiva Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Diltiazem$2.3M 2Furosemide

Product Portfolio — Top 4 by Export Value

Maiva Pharma Private Limited exports 4 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Diltiazem	Cardiovascular	$2.3M	47	12.9%	2
2	Furosemide	Diuretics	$1.6M	33	2.3%	11
3	Ephedrine	Respiratory & OTC	$350.0K	7	1.6%	12
4	Metoclopramide	Gastrointestinal	$229.4K	5	1.0%	10

Maiva Pharma Private Limited exports 4 pharmaceutical products across 4 therapeutic categories with a total export value of $4.5M. The top category is Cardiovascular (51.0% of portfolio), followed by Diuretics (36.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Maiva Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Maiva Pharma's primary manufacturing facility is located in Hosur, Tamil Nadu, approximately 70 kilometers south of Bengaluru International Airport and 310 kilometers east of Chennai Port. The plant spans 5 acres and is equipped with four manufacturing lines capable of producing both aseptically filled and terminally sterilized products. The facility has received approvals from the US FDA and EU GMP, underscoring its compliance with international quality standards.

In 2024, Maiva Pharma expanded its manufacturing capabilities by establishing Maiva Life Sciences (MLS), a fully owned subsidiary. MLS is a state-of-the-art sterile injectable manufacturing facility under development in Shoolagiri, Hosur. The site is planned to house six manufacturing lines in Phase 1, designed to support advanced sterile injectable production capabilities.

3Key Leadership

Dr. Bhaskar Krishna serves as the Managing Director and Chief Executive Officer of Maiva Pharma. Since joining the company in 2013, Dr. Krishna has been instrumental in expanding Maiva Pharma's presence in regulated markets such as Canada, the European Union, and Australia. His leadership has facilitated the company's entry into these markets and accelerated the inspection process by Health Canada, followed by EU inspection and approval.

Mr. Shivananda Hegde holds the position of Chief Financial Officer and Company Secretary. Joining Maiva Pharma in 2007, Mr. Hegde has played various roles within the organization, from Financial Controller to Company Secretary. In addition to his responsibilities as CFO and Company Secretary, he also heads the Human Resource department.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Maiva Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Maiva Pharma has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Hosur, Tamil Nadu, has received approvals from the US FDA and EU GMP, demonstrating compliance with stringent international quality standards.

In the United States, Maiva Pharma has secured 19 Abbreviated New Drug Application (ANDA) approvals, indicating a strong foothold in the generic pharmaceutical market. The company's expansion into the European Union and Australia further underscores its commitment to meeting global regulatory requirements and delivering quality pharmaceutical products.

2Emerging Markets

Maiva Pharma has also made strategic inroads into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these markets, enabling the supply of quality pharmaceutical products to a broader global audience.

3Geographic Strategy

Maiva Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Maiva Pharma's manufacturing facility in Hosur, Tamil Nadu, is registered with the US FDA, indicating compliance with US regulatory standards. The company has secured 19 ANDA approvals, reflecting its active participation in the US generic pharmaceutical market. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, the company's adherence to US FDA standards suggests a robust regulatory standing.

2WHO & EU GMP

Maiva Pharma's manufacturing facility has received approvals from the European Union's Good Manufacturing Practice (EU GMP) standards, demonstrating compliance with stringent European quality requirements. Additionally, the company's adherence to WHO prequalification standards facilitates access to various international markets, including those in Africa, Latin America, and Southeast Asia.

3CDSCO & Indian Regulatory

Maiva Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Hosur, Tamil Nadu, is registered with the CDSCO, ensuring compliance with Indian pharmaceutical manufacturing standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed.

Maiva Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Maiva Pharma operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's significant presence in regulated markets such as the United States, European Union, and Australia positions it as a notable competitor. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, further enhances its manufacturing capabilities, potentially strengthening its competitive position.

2Key Differentiators

Maiva Pharma's key differentiators include its specialized focus on sterile injectables, adherence to international quality standards, and a robust manufacturing facility with US FDA and EU GMP approvals. The company's commitment to quality, compliance, and ethical business practices has earned it recognition in regulated markets such as the United States, European Union, and Australia.

3Strategic Position

Maiva Pharma's current strategic direction emphasizes the development and manufacturing of sterile injectables, with a focus on expanding its presence in regulated markets. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, indicates a forward-looking approach to enhancing manufacturing capabilities and market reach. The company's adherence to international quality standards and its expansion into emerging markets reflect a strategic vision aimed at sustainable growth and global competitiveness.

Buyer Due Diligence Brief — Evaluating Maiva Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Maiva Pharma has demonstrated a strong track record in pharmaceutical manufacturing, with a focus on sterile injectables. The company's manufacturing facility in Hosur, Tamil Nadu, has received approvals from the US FDA and EU GMP, underscoring its compliance with international quality standards. The establishment of Maiva Life Sciences in Shoolagiri, Hosur, further enhances its manufacturing capabilities, indicating a commitment to meeting global demand.

2Certifications to Verify

Importers should verify the following certifications when considering Maiva Pharma as a supplier:

US FDA Registration: Confirm the company's registration status with the US FDA to ensure compliance with US regulatory standards.

EU GMP Certification: Verify the EU GMP certification to ensure adherence to European manufacturing standards.

WHO Prequalification: Check for WHO prequalification status to facilitate access to various international markets.

Frequently Asked Questions — Maiva Pharma Private Limited

How many pharmaceutical products does Maiva Pharma Private Limited export from India?

Maiva Pharma Private Limited exports 4 pharmaceutical products across 4 therapeutic categories. The top exports are Diltiazem ($2.3M), Furosemide ($1.6M), Ephedrine ($350.0K), Metoclopramide ($229.4K). Total export value is $4.5M.

What is Maiva Pharma Private Limited's total pharmaceutical export value?

Maiva Pharma Private Limited's total pharmaceutical export value is $4.5M, based on 92 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Maiva Pharma Private Limited cover?

Maiva Pharma Private Limited exports across 4 therapeutic categories. The largest are Cardiovascular (51.0%, 1 products), Diuretics (36.3%, 1 products), Respiratory & OTC (7.7%, 1 products).

Get Full Maiva Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.